IFNA1 and Dravet syndrome: Later in life, JAK inhibition may benefit those with a high burden of autoimmune conditions more prevalent in DS, such as AITD, celiac disease, and various immune skin conditions, all of which have been tied in the general population to either IFN hyperactivity or cytokines shown here to associate with IFN scores in DS (60, 61).